Ustekinumab could fulfil unmet need in PsA
Ustekinumab has the potential to fulfil a significant unmet need in PsA, say the authors of the PSUMMIT II trial.
PSA International saw net profit slump 46% to S$1.04bn last year, down from S$1.9bn a year earlier as a result of lower yields, higher operating costs, impairment provisions and lower divestment gains.